ClinicalTrials.gg
CompletedNCT04683042Updated Nov 4, 2026Results posted

Fibromyalgia TENS in Physical Therapy Study (TIPS): an Embedded Pragmatic Clinical Trial

An interventional study of Transcutaneous Electrical Nerve Stimulation (TENS) with PT and PT only in Fibromyalgia, sponsored by Kathleen Sluka. Completed at 6 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Kathleen Sluka · Not applicable, Interventional, and Treatment

How we know

Updated Nov 4, 2026Results postedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
459
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.

Enrollment
29th of 320
459 · median 72
Started
2021
with 18 others
No phase
167 of 369
34 open now
Registered
284th of 369
by date

Among the 369 studies in Fibromyalgia with a site in United States, this one is the 29th largest by enrollment of the 320 interventional ones that give a count, is one of 19 that started in 2021, is one of 167 with no phase, and was the 284th registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Fibromyalgia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if addition of Transcutaneous Electrical Nerve Stimulation (TENS) to routine physical therapy improves movement-evoked pain in patients with fibromyalgia (FM).

The study will also determine if addition of TENS to routine physical therapy (PT) improves disease activity and symptoms, increases adherence to physical therapy, increases the likelihood of meeting patient specific functional goals, and reduces medication use.

Read the detailed description

This study is a pragmatic clinical trial in outpatient PT practices utilizing cluster randomization by healthcare system and facility size. Sites will be randomized to enroll all eligible and consented participants with FM to TENS with PT, or PT only (no TENS). We are identifying 25-35 clinics across 6 healthcare systems in both rural and urban settings. We will enroll 450 patients that self report a clinician diagnosis of FM. At each site, TENS (or no TENS) will be applied during each visit along with individualized PT treatment specified by the physical therapist. Participants randomized to TENS intervention sites will receive TENS units and electrodes at baseline to be applied to the cervical and lumbar regions. Participants will take the units home and bring the units back to their PT clinic visits with instructions for use at home while active and during their exercises. The physical therapist at each clinic will complete routine documentation of treatment. In addition to the primary and secondary outcomes, Electronic Health Record data variables will be collected as exploratory outcomes. Variables including adherence to treatment will be extracted from each site's Electronic Health Record. Patient-reported assessments will be obtained from the participant's at home the day of their second PT visit (Baseline) and at 30, 60 (primary outcome), 90, and 180 days following enrollment. The primary and secondary outcome assessments will be comparing TENS and no TENS groups in terms of changes from baseline to 60 days.

Participants will be identified after they are referred for PT for treatment of primary fibromyalgia (FM) or chronic pain (pain lasting more than three months). At their first (intake) physical therapy visit, they will be provided information about the study that can be accessed on paper or on-line. They will perform an electronic screening form on the first visit if interested in participating. Participants will provide e-consent after eligibility is confirmed at the initial PT visit. At the second PT visit after e-consent is signed, participants will be provided instructions on logging onto REDCap for data capture and accessing the case report forms. Participants enrolled at a TENS site will then be instructed in use of TENS and the TENS unit with electrodes will be provided. Those participants enrolled at a no TENS site will skip the instruction in use of TENS but will then receive instructions along with the TENS units at day 65. Participants will be instructed to capture all baseline assessments at home before their next PT visit before and following their first TENS treatment (or no TENS) at home (day 1). At 30, 60, 90, and 180 days following enrollment, participants will complete the same assessments at home including pain ratings at rest and with movement along with questionnaires. The primary and secondary outcome assessments will be comparing TENS and no TENS groups in terms of changes from baseline to 60 days.

03

Conditions studied

  • Fibromyalgia

Keywords

  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • chronic pain
  • fibromyalgia
  • movement pain
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 until 99.
  2. Clinician diagnosis of FM
  3. Referred for land-based PT
  4. Referred for treatment for FM or chronic pain (pain lasting more than 3 months)
  5. Able to provide .
  6. Fluent in reading English
  7. Willing to use TENS

Exclusion criteria

Exclusion Criteria:

  1. to TENS use including:

    1. Pacemaker, defibrillator, implanted neurostimulator or implanted device
    2. Epilepsy
    3. Currently pregnant or plan to become pregnant in the next 6 months
    4. Allergic reaction to patches with gel
    5. Current treatment for cancer
  2. Currently enrolled in another pain control study
  3. Use of TENS within the last 30 days
  4. Clinically unstable medical or psychiatric issues
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
459 participants (actual)

Study arms

  • Active comparator
    TENS with PT

    TENS with PT group: The TENS with PT group will receive usual PT care and following enrollment, during the second PT visit, participants will receive TENS units and instruction on use of the TENS units. TENS will be applied to the upper and lower back with butterfly electrodes using the following parameters: mixed frequency (2-125Hz), strong but comfortable intensity, variable pulse duration from 100-250 microseconds. TENS to be applied when the patient is active and doing exercises at home and during PT sessions for 30 minutes at least 2 hours per day. The TENS with PT group will complete TENS use to the end of the study at 6 months.

    Device: Transcutaneous Electrical Nerve Stimulation (TENS) with PT

  • Other
    No TENS with PT

    The No TENS group will receive usual PT care until the primary endpoint timeframe of 60 days. After completion of the research homework at 60 days, TENS units will be mailed to the participants and a study team member will complete virtual TENS instruction. The no TENS group will complete TENS to the end of the study at 6 months.

    Other: PT only

Interventions

  • DeviceTranscutaneous Electrical Nerve Stimulation (TENS) with PT

    Use of TENS units along with routine PT therapy

  • OtherPT only

    Routine PT therapy only

06

What researchers measure

Primary outcomes

  1. Change in Movement-evoked Pain During the Sit and Stand Test

    Numeric rating scale of -10 to 10 for change in movement-evoked pain. Change score was defined as pain scores at Day 60 (measured by 11-point NRS) minus Day 1(measured by 11-point NRS). Therefore, a negative score represents an improvement in outcome.

    Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home

Secondary outcomes

  1. Change in the Resting Pain Score

    Numeric rating scale of -10 to 10 for change in resting pain. Change score was defined as pain scores at Day 60 (measured by 11-point NRS) minus Day 1(measured by 11-point NRS). Therefore, a negative score represents an improvement in outcome.

    Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home

  2. Change in Pain Interference (BPI)

    Numeric rating scale of -10 to 10 for change in pain interference. Change score was defined as pain scores at Day 60 (measured by 11 items measuring pain severity and interference with daily activities on a 0-10 scale) minus Day 1(measured by 11 items measuring pain severity and interference with daily activities on a 0-10 scale). Therefore, a negative score represents an improvement in outcome.

    Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home

  3. Change in FM Disease Activity (FIQR)

    The Revised Fibromyalgia Impact Questionnaire (FIQR; 0-100) is a 21-item, disease-specific patient-reported outcome measure that assesses function, overall impact, and symptoms of fibromyalgia. Change score (-100, 100) was defined as FIQR at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.

    Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home

  4. Change in Resting Fatigue

    The severity of fatigue is measured with a 0 to 10 scale where 0 is no fatigue and 10 is worst fatigue imaginable. Change score is on a numeric rating scale of -10 to 10 for change resting fatigue pain and was defined as pain scores at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.

    Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home

  5. Change in Movement-evoked Fatigue

    Fatigue during a five times sit and stand test is measured with a 0 to 10 numeric rating scale with 0 as no fatigue and 10 as the worst fatigue imaginable. Change score was defined as movement fatigue scores at Day 60 minus Day 1 resulting in a numeric rating scale of -10 to 10 for change movement-evoked fatigue. Therefore, a negative score represents an improvement in outcome.

    Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home

  6. Change in Multidimensional Assessment of Fatigue (MAF)

    MAF (1-50) is composed of 16 items measuring fatigue according to four dimensions: degree and severity, distress that it causes, timing of fatigue, and impact on various activities of daily living. Change score was defined as MAF at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.

    Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home

  7. Change in Rapid Assessment of Physical Activity (RAPA) Aerobic

    RAPA Aerobic (0-5 Low to High Scale) is composed of 5 items evaluating current level of physical activity. Change score was defined as RAPA Aerobic at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.

    Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home

  8. Change in Rapid Assessment of Physical Activity (RAPA) Strength and Flexibility

    RAPA Strength and Flexibility (0-4, Low to High Scale) is composed of 4 items evaluating current level of physical activity. Change score was defined as RAPA Strength and Flexibility at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.

    Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home

  9. Patient Global Impression of Change (PGIC) (Improved, No Change, Worse)

    Evaluates overall health status as perceived by the patient in a seven-point single-item scale ranging from 'very much worse' to 'very much improved'

    Time frame: Day 60 +/- 5 days Home

07

Results

Posted Nov 4, 2026

Participant flow

36 Sites from 6 health care systems were screened. Participants were enrolled after completion of electronic informed consent between January 22, 2021, and September 31, 2024, with final data collected in March 2025. On PT visit 1, patients were assessed for eligibility with an electronic screening survey (REDCap). A total of 958 participants were screened, 459 participants enrolled, and 384 completed baseline data collection (modified intention to treat \[mITT\]).

Enrollment
Participant flow — Enrollment
MilestoneTENS With PTNo TENS With PT
Started230229
Completed230229
Not completed00
Day 1 (mITT)
Participant flow — Day 1 (mITT)
MilestoneTENS With PTNo TENS With PT
Started191193
Completed191193
Not completed00
Day 60
Participant flow — Day 60
MilestoneTENS With PTNo TENS With PT
Started171173
Completed171173
Not completed00

Outcome measures

PrimaryChange in Movement-evoked Pain During the Sit and Stand Test

Numeric rating scale of -10 to 10 for change in movement-evoked pain. Change score was defined as pain scores at Day 60 (measured by 11-point NRS) minus Day 1(measured by 11-point NRS). Therefore, a negative score represents an improvement in outcome.

Time frame:
Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Reported as:
Mean · units
Change in Movement-evoked Pain During the Sit and Stand Test
unitsTENS With PTNo TENS With PT
Change in Movement-evoked Pain During the Sit and Stand Test-1 (-1.4 to -0.7)0 (-0.3 to 0.3)
Statistical analysis
  • TENS With PT vs No TENS With PT · Mixed Models Analysis · p = <0.001 (Unadjusted two-sided p-value) · Mean difference (final values): -1.2 · 95% CI -1.6 to -0.7Estimated difference between the two treatment groups above are based on multiple imputation.
SecondaryChange in the Resting Pain Score

Numeric rating scale of -10 to 10 for change in resting pain. Change score was defined as pain scores at Day 60 (measured by 11-point NRS) minus Day 1(measured by 11-point NRS). Therefore, a negative score represents an improvement in outcome.

Time frame:
Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Reported as:
Mean · units
Change in the Resting Pain Score
unitsTENS With PTNo TENS With PT
Change in the Resting Pain Score-1 (-1.3 to -0.7)-0.1 (-0.4 to 0.2)
Statistical analysis
  • TENS With PT vs No TENS With PT · Mixed Models Analysis · p = <0.001 (Unadjusted two-sided p-value) · Mean difference (final values): -1.0 · 95% CI -1.4 to -0.5Estimated difference in change from day 1 to day 60 between the two treatment groups above are obtained from the LMM model.
SecondaryChange in Pain Interference (BPI)

Numeric rating scale of -10 to 10 for change in pain interference. Change score was defined as pain scores at Day 60 (measured by 11 items measuring pain severity and interference with daily activities on a 0-10 scale) minus Day 1(measured by 11 items measuring pain severity and interference with daily activities on a 0-10 scale). Therefore, a negative score represents an improvement in outcome.

Time frame:
Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Reported as:
Mean · units
Change in Pain Interference (BPI)
unitsTENS With PTNo TENS With PT
Change in Pain Interference (BPI)-0.9 (-1.2 to -0.6)-0.3 (-0.5 to -0.0)
Statistical analysis
  • TENS With PT vs No TENS With PT · Mixed Models Analysis · p = 0.004 (Unadjusted two-sided p-value) · Mean difference (final values): -0.7 · 95% CI -1.1 to -0.2Estimated difference in change from day 1 to day 60 between the two treatment groups above are obtained from the LMM model.
SecondaryChange in FM Disease Activity (FIQR)

The Revised Fibromyalgia Impact Questionnaire (FIQR; 0-100) is a 21-item, disease-specific patient-reported outcome measure that assesses function, overall impact, and symptoms of fibromyalgia. Change score (-100, 100) was defined as FIQR at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.

Time frame:
Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Reported as:
Mean · units
Change in FM Disease Activity (FIQR)
unitsTENS With PTNo TENS With PT
Change in FM Disease Activity (FIQR)-7.3 (-9.4 to -5.2)-2.9 (-4.7 to -1.0)
Statistical analysis
  • TENS With PT vs No TENS With PT · Mixed Models Analysis · p = 0.009 (Unadjusted two-sided p-value) · Mean difference (final values): -4.1 · 95% CI -7.0 to -1.1Estimated difference in change from day 1 to day 60 between the two treatment groups above are obtained from the LMM model.
SecondaryChange in Resting Fatigue

The severity of fatigue is measured with a 0 to 10 scale where 0 is no fatigue and 10 is worst fatigue imaginable. Change score is on a numeric rating scale of -10 to 10 for change resting fatigue pain and was defined as pain scores at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.

Time frame:
Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Reported as:
Mean · units
Change in Resting Fatigue
unitsTENS With PTNo TENS With PT
Change in Resting Fatigue-0.8 (-1.2 to -0.5)-0.1 (-0.4 to 0.2)
Statistical analysis
  • TENS With PT vs No TENS With PT · Mixed Models Analysis · p = 0.006 (Unadjusted two-sided p-value) · Mean difference (final values): -0.8 · 95% CI -1.3 to -0.2Estimated difference in change from day 1 to day 60 between the two treatment groups above are obtained from the LMM model.
SecondaryChange in Movement-evoked Fatigue

Fatigue during a five times sit and stand test is measured with a 0 to 10 numeric rating scale with 0 as no fatigue and 10 as the worst fatigue imaginable. Change score was defined as movement fatigue scores at Day 60 minus Day 1 resulting in a numeric rating scale of -10 to 10 for change movement-evoked fatigue. Therefore, a negative score represents an improvement in outcome.

Time frame:
Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Reported as:
Mean · units
Change in Movement-evoked Fatigue
unitsTENS With PTNo TENS With PT
Change in Movement-evoked Fatigue-1.1 (-1.5 to -0.7)-0.0 (-0.3 to 0.3)
Statistical analysis
  • TENS With PT vs No TENS With PT · Mixed Models Analysis · p = <0.001 (Unadjusted two-sided p-value) · Mean difference (final values): -1.2 · 95% CI -1.7 to -0.6Estimated difference in change from day 1 to day 60 between the two treatment groups above are obtained from the LMM model.
SecondaryChange in Multidimensional Assessment of Fatigue (MAF)

MAF (1-50) is composed of 16 items measuring fatigue according to four dimensions: degree and severity, distress that it causes, timing of fatigue, and impact on various activities of daily living. Change score was defined as MAF at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.

Time frame:
Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Reported as:
Mean · units
Change in Multidimensional Assessment of Fatigue (MAF)
unitsTENS With PTNo TENS With PT
Change in Multidimensional Assessment of Fatigue (MAF)-3.2 (-4.6 to -1.8)-0.9 (-2.1 to 0.2)
Statistical analysis
  • TENS With PT vs No TENS With PT · Mixed Models Analysis · p = 0.05 (Unadjusted two-sided p-value) · Mean difference (final values): -1.9 · 95% CI -3.8 to 0.0Estimated difference in change from day 1 to day 60 between the two treatment groups above are obtained from the LMM model.
SecondaryChange in Rapid Assessment of Physical Activity (RAPA) Aerobic

RAPA Aerobic (0-5 Low to High Scale) is composed of 5 items evaluating current level of physical activity. Change score was defined as RAPA Aerobic at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.

Time frame:
Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Reported as:
Mean · units
Change in Rapid Assessment of Physical Activity (RAPA) Aerobic
unitsTENS With PTNo TENS With PT
Change in Rapid Assessment of Physical Activity (RAPA) Aerobic0.1 (-0.1 to 0.3)0.2 (0 to 0.4)
Statistical analysis
  • TENS With PT vs No TENS With PT · Mixed Models Analysis · p = 0.473 (Unadjusted two-sided p-value) · Mean difference (final values): 0.10 · 95% CI -0.2 to 0.4LMM with random effects for treatment nested within clinic and healthcare system and fixed effects for TRT arm, clinic size, and baseline outcomes.
SecondaryChange in Rapid Assessment of Physical Activity (RAPA) Strength and Flexibility

RAPA Strength and Flexibility (0-4, Low to High Scale) is composed of 4 items evaluating current level of physical activity. Change score was defined as RAPA Strength and Flexibility at Day 60 minus Day 1. Therefore, a negative score represents an improvement in outcome.

Time frame:
Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Reported as:
Mean · units
Change in Rapid Assessment of Physical Activity (RAPA) Strength and Flexibility
unitsTENS With PTNo TENS With PT
Change in Rapid Assessment of Physical Activity (RAPA) Strength and Flexibility0.3 (0.1 to 0.4)0.4 (0.2 to 0.6)
Statistical analysis
  • TENS With PT vs No TENS With PT · Mixed Models Analysis · p = 0.793 (Unadjusted two-sided p-value) · Mean difference (final values): -0.0 · 95% CI -0.3 to 0.2LMM with random effects for treatment nested within clinic and healthcare system and fixed effects for TRT arm, clinic size, and baseline outcomes.
SecondaryPatient Global Impression of Change (PGIC) (Improved, No Change, Worse)

Evaluates overall health status as perceived by the patient in a seven-point single-item scale ranging from 'very much worse' to 'very much improved'

Time frame:
Day 60 +/- 5 days Home
Reported as:
Count of participants · Participants
Patient Global Impression of Change (PGIC) (Improved, No Change, Worse)
ParticipantsTENS With PTNo TENS With PT
Improved12086
No Change3258
Worse1426
Statistical analysis
  • TENS With PT vs No TENS With PT · Chi-squared · p = <0.001 (Unadjusted two-sided p-value) · Odds ratio (or): 2.5 · 95% CI 1.6 to 4.0Chi-square test comparing %improved vs %(No Change + Worse) between TRT arm. Chi-square test with 2 Degrees of freedom.

Adverse events

Collected over "From Day 1 to Day 180 homework assessments for "TENS With PT" and "No TENS With PT" Arms/Groups; from Day 60 to 6-month follow-up for "Participants in No TENS With PT that started TENS with PT at Day 60" Arm/Group". Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TENS With PT (Day 1 - 180)0/179 (0%)0/179 (0%)71/179 (39.7%)
No TENS With PT (Day 1 - 60)0/179 (0%)0/179 (0%)—
No TENS With PT (Day 60 - 180)0/179 (0%)0/179 (0%)38/179 (21.2%)
Most frequent other events
Most frequent other events
EventTENS With PT (Day 1 - 180)No TENS With PT (Day 1 - 60)No TENS With PT (Day 60 - 180)
OtherProduct Issues48/179—24/179
Skin irritation with electrodesSkin and subcutaneous tissue disorders17/179—7/179
Itchiness with TENSSkin and subcutaneous tissue disorders16/179—6/179
Pain with TENSNervous system disorders15/179—12/179
Anxiety with TENSPsychiatric disorders11/179—4/179
Nausea with TENSGastrointestinal disorders3/179—1/179

Baseline characteristics

These represent the number of participants from our modified intention to treat population (i.e. who completed day 1 homework assessment)

Age, Continuous
Age, Continuous(Years)TENS With PTNo TENS With PTTotal
Mean52.6 ± 15.553.9 ± 14.853.2 ± 15.2
Sex/Gender, Customized
Sex/Gender, Customized(Participants)TENS With PTNo TENS With PTTotal
Female175176351
Unknown/Prefer not to answer/Missing257
Male141226
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TENS With PTNo TENS With PTTotal
American Indian or Alaska Native123
Asian303
Native Hawaiian or Other Pacific Islander022
Black or African American171532
White156159315
More than one race347
Unknown or Not Reported111122
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TENS With PTNo TENS With PTTotal
Hispanic or Latino71926
Not Hispanic or Latino170156326
Unknown or Not Reported141832
08

Study locations

6 sites
  • University of Illinois at Chicago
    Chicago, Illinois 60607, United States
  • Rock Valley Physical Therapy
    Moline, Illinois 61265, United States
  • Kepros Physical Therapy and Performance
    Cedar Rapids, Iowa 52404, United States
  • Genesis Physical Therapy
    Davenport, Iowa 52807, United States
  • Big Stone Therapies (BST)
    Big Stone City, South Dakota 57216, United States
  • Advanced Physical Therapy Sport Medicine
    Appleton, Wisconsin 54913, United States
09

References and documents

Publications

  • Yarasir Gillette E, Vance KG, Bayman EO, Dailey DL, Vance CGT, Chimenti RL, Crofford LJ, Van Gorp BJ, Johnson EM, Archer KR, Schacht Reisinger H, Zimmerman MB, Sluka KA, Berardi G. Sociodemographic factors, but not rurality, explain limited variance in fibromyalgia severity: a secondary analysis of 2 randomized clinical trials. Pain Med. 2026 Nov 1;27(11):1210-1220. doi: 10.1093/pm/pnag088. PubMed 42434958 ↗
  • Dailey DL, Vance CGT, Van Gorp BJ, Johnson EM, Post AA, Chimenti RL, Vance KG, Franck C, Sault J, Yarasir E, Reisinger HS, Anderson A, Anderson J, Capelle R, Crouch A, Donatelle J, Kaster D, Kepros T, Nicklies E, Rein B, Worth R, Balinski M, Lafontant DE, Slade EJ, Jiang F, Ecklund D, Neill-Hudson T, Koepp M, Costigan M, Spencer M, Archer KR, Zimmerman BM, Bayman EO, Crofford LJ, Sluka KA; Clinician Group. Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With Fibromyalgia: A Cluster Randomized Clinical Trial. JAMA Netw Open. 2026 Mar 2;9(3):e262450. doi: 10.1001/jamanetworkopen.2026.2450. PubMed 41893844 ↗
  • Post AA, Dailey DL, Bayman EO, Chimenti RL, Costigan M, Franck C, Huff T, Johnson E, Koepp M, Lafontant DE, McCabe ME, Neill-Hudson T, Vance CGT, Van Gorp B, Zimmerman BM, Ecklund D, Crofford LJ, Sluka KA. The Fibromyalgia Transcutaneous Electrical Nerve Stimulation in Physical Therapy Study Protocol: A Multisite Embedded Pragmatic Trial. Phys Ther. 2022 Nov 6;102(11):pzac116. doi: 10.1093/ptj/pzac116. PubMed 36036838 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The current study is expected to generate patient-reported outcomes for individuals with fibromyalgia across a broad spectrum of domains, pain, fatigue, function, psychological factors, and quality of life. We will also collect some data from the electronic health record about number of physical therapy visits, Current Protocol Terminology (CPT) codes for treatments, and the patient-specific functional scale. In addition, we will have TENS usage data downloaded from the TENS devices that will show the number of minutes of TENS use and the number of 30 minute sessions completed. Data will be collected prior to the intervention (baseline data) and 30, 60, 90 and 180 days after enrollment.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Analysis datasets will be made available at the time of publication of the primary manuscript. Complete datasets and accompanying resources will be deposited to the designated NIH Helping to End Addiction Long-term initiative (HEAL) data repository after the completion of the primary aim manuscript.

Access criteria: In accordance with NIH Collaboratory policies, we will prepare the primary analysis datasets (at a minimum) for submission to the Collaboratory Coordinating Center. In accordance with International Committee of Medical Journal Editors (ICMJE) policies, we will prepare the primary analysis datasets for review and reproducibility by peer-reviewed journals. We will prepare the final datasets and accompanying resource documents for final deposit to the designated NIH HEAL data repository. Publications will be made available to the public using open access publishing, so they become available immediately to the public. All publications will be accessible through PubMED, google scholar, and available to the public through open access.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Mar 2025, 49 months.

Results were first posted in Nov 2026, 1 year 7 months after primary completion.

Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's 49 months is above that.

Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2020
First posted
Dec 24, 2020
StartActual
Jan 22, 2021
Primary completionActual
Mar 11, 2025
CompletionActual
Mar 11, 2025
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedReduction of movementChange in Movement-evoked pain (0-10 Low to High scale) duringPain During the Sit and Stand TestTime frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Nov 4, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42434958 ↗
Nov 4, 2026
Secondary outcomes
5 edited, 4 added, 3 removed
What changed in the outcomes
  • EditedChange in the resting pain score (0 - 10 Low to High scale)Resting Pain ScoreTime frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
  • EditedChange in FM Disease activityActivity (FIQR) (0-10 Low to High Scale)Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
  • EditedChange in Multidimensional assessmentAssessment of fatigueFatigue (MAF) (0-10 Low to High Scale)Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
  • EditedChange in Rapid assessmentAssessment of physical activityPhysical Activity (RAPA) (0-10 Low to High Scale)AerobicTime frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
  • EditedPatient global impressionGlobal Impression of changeChange (PGIC) (0-6 ScaleImproved, No Change, Worse)Time frame: Day 60 +/- 5 days Home
  • AddedChange in Pain Interference (BPI)Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
  • AddedChange in Resting FatigueTime frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
  • AddedChange in Movement-evoked FatigueTime frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
  • AddedChange in Rapid Assessment of Physical Activity (RAPA) Strength and FlexibilityTime frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
  • RemovedPain interference (BPI) (0-10 Low to High Scale)Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
  • RemovedResting fatigue (NRS) (0-10 Low to High Scale)Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
  • RemovedMovement-evoked fatigue (NRS) (0-10 Low to High Scale)Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
Nov 4, 2026
Design
Phase 3→Not applicable
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42434958 ↗
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedReduction of movementChange in Movement-evoked pain (0-10 Low to High scale) duringPain During the Sit and Stand TestTime frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
    Secondary outcomes 5 edited, 4 added, 3 removed
    What changed in the outcomes
    • EditedChange in the resting pain score (0 - 10 Low to High scale)Resting Pain ScoreTime frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
    • EditedChange in FM Disease activityActivity (FIQR) (0-10 Low to High Scale)Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
    • EditedChange in Multidimensional assessmentAssessment of fatigueFatigue (MAF) (0-10 Low to High Scale)Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
    • EditedChange in Rapid assessmentAssessment of physical activityPhysical Activity (RAPA) (0-10 Low to High Scale)AerobicTime frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
    • EditedPatient global impressionGlobal Impression of changeChange (PGIC) (0-6 ScaleImproved, No Change, Worse)Time frame: Day 60 +/- 5 days Home
    • AddedChange in Pain Interference (BPI)Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
    • AddedChange in Resting FatigueTime frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
    • AddedChange in Movement-evoked FatigueTime frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
    • AddedChange in Rapid Assessment of Physical Activity (RAPA) Strength and FlexibilityTime frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
    • RemovedPain interference (BPI) (0-10 Low to High Scale)Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
    • RemovedResting fatigue (NRS) (0-10 Low to High Scale)Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
    • RemovedMovement-evoked fatigue (NRS) (0-10 Low to High Scale)Time frame: Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home
    Design Phase 3→Not applicable
    + 3 other changes: verification date, responsible party and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04683042
Lead sponsor
Kathleen Sluka
Responsible party
Kathleen Sluka (Kathleen A. Sluka, PhD, PT, FAPTA, University of Iowa) — Sponsor-investigator
First posted
Dec 24, 2020
Start date
Jan 22, 2021
Primary completion
Mar 11, 2025
Completion
Mar 11, 2025
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

Kathleen Sluka, PhD, PT
principal investigator · University of Iowa
Leslie Crofford, MD
principal investigator · Vanderbilt University
Dana Dailey, PhD, PT
study director · University of Iowa

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion